Study on the efficacy and toxicity related gene polymorphism in non-small cell lung cancer patients with gemcitabine chemotherapy

VernacularTitle:晚期非小细胞肺癌患者吉西他滨化疗疗效及毒性相关基因多态性的研究
Author: Qinxiang GUO
Publication Type:Journal Article
Keywords: Carcinoma,non-small-cell lung; Gemcitabine; ERCC1 gene; Efficacy; Toxicity
From: Chinese Journal of Primary Medicine and Pharmacy 2013;20(22):3377-3378
CountryChina
Language:Chinese
Abstract: Objective To study the efficacy and toxicity related gene polymorphism in non-small cell lung cancer patients with gemcitabine chemotherapy.Methods 40 patients with non-smallcell lung cancer were chosen in the present study.The leukocyte DNA was extracted from blood samples.ERCC1 118 genotypes were detected by PCR-RFLP.The relationship between ERCC1 118 genotype and the chemotherapy efficacy and toxicity of patients received gemcitabine was analyzed.Results The age,gender,pathological type,clinical stage,and other factors had no relation with the treatment effects (P ＞ 0.05).The frequency of C/C genotype was 55.0％ (22/40),the frequency of C/T +T/T genotype was 45.0％ (18/40).The effective rate was 45.5％ in patients carrying the C/C gene,The effective rate was 22.2％ in patients carrying the C/T + T/T gene,the difference between the two groups was not statistically significant (x2 =2.3488,P ＞ 0.05).Conclusion The ERCC1 gene polymorphism is not significantly correlated with the efficacy and toxicity of gemcitabine chemotherapy.